Renoprotec

Quick links to important sections

Renoprotec

Method of action: Hypotensive

Treatment option: Hypertension

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Renoprotec

What is Renoprotec?

Renoprotec is a pharmacological intervention categorized as a selective aldosterone synthase inhibitor. It is designed to target specific physiological pathways involved in the regulation of mineralocorticoid levels, which play a central role in fluid balance and cardiovascular health.

Mechanism of Action

The primary function of Renoprotec is the inhibition of the enzyme aldosterone synthase. This enzyme is responsible for the final stages of aldosterone production in the adrenal glands. By reducing the synthesis of aldosterone, the medication aims to mitigate the effects of mineralocorticoid excess, which can contribute to various pathological states.

Unlike non-selective mineralocorticoid receptor antagonists, Renoprotec focuses on the production of the hormone itself rather than just blocking its receptors. This mechanism is intended to provide a more targeted approach to managing hormonal imbalances without significantly affecting the production of other essential steroids, such as cortisol.

Therapeutic Focus

Renoprotec is primarily investigated for its potential role in managing conditions characterized by overactivation of the renin-angiotensin-aldosterone system. This includes research into its application for:

  • Chronic Kidney Disease: Exploring how the reduction of aldosterone levels may influence the progression of renal decline and the management of protein excretion in the urine.
  • Hypertension: Investigating its efficacy in lowering blood pressure, particularly in cases that do not respond sufficiently to standard therapies.
  • Heart Failure: Studying the impact of reduced hormonal stress on cardiac structure and function.

Clinical Context

As a relatively new class of therapy, Renoprotec represents an evolution in the treatment of cardiorenal metabolic syndromes. It is utilized in clinical settings to address the underlying hormonal drivers of organ damage, offering an alternative pathway for patients where traditional sodium and fluid management strategies require additional support.

What side effects are possible with Renoprotec?

The official safety documentation for Renoprotec (Moexipril hydrochloride) outlines adverse reactions and specific safety patterns consistent with the Angiotensin-Converting Enzyme (ACE) inhibitor class. This information is classified by government health authorities based on observed frequency and the body systems affected.

Documented Adverse Reactions and Frequency

Adverse reactions are formally categorized based on their documented incidence in clinical trials:

  • Common Reactions: These are observed in 1% to 10% of patients and frequently include headache, dizziness, and a persistent, dry cough. Other common effects include general disorders like fatigue.
  • Uncommon Reactions: These are reported in fewer than 1 in 100 patients. They may involve the Gastrointestinal System, presenting as nausea, diarrhea, or abdominal pain.

Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights specific serious adverse reactions. The most critical is angioedema, a rapid swelling of deep tissue that can affect the face, throat, or intestines. Due to the risk of airway obstruction, a history of angioedema related to any prior ACE inhibitor treatment is an absolute contraindication.

A common time-related safety pattern involves hypotension (abnormally low blood pressure), which is often described as being more likely upon the initiation of treatment or during dose escalation.

Population-Specific Safety Notes

The medication is contraindicated during the second and third trimesters of pregnancy due to established safety risks to the fetus. Patients with existing renal impairment require increased safety monitoring, as the drug's active metabolite accumulates with decreased kidney function. Official notes also indicate that the risk of angioedema may be higher in Black patients.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Renoprotec (Moexipril hydrochloride) can lead to severe physiological manifestations primarily related to excessive inhibition of the Renin-Angiotensin-Aldosterone System. The most frequent clinical presentation documented in regulatory sources is severe or symptomatic hypotension (profound low blood pressure), which may be prolonged and potentially fatal in severe cases.


Life-Threatening Risks and Emergency Action

Potential Life-Threatening Outcome Regulator-Mandated Action
Airway Obstruction due to angioedema (swelling of the face, throat, or tongue). Seek immediate medical attention and contact emergency services.
Prolonged Hypotension or circulatory shock. Seek immediate medical attention for supportive management.

Official Management and Monitoring

For confirmed or suspected overdose, immediate medical attention is required. Management includes supportive measures such as the administration of Intravenous Fluids and, if necessary, Inotropic Support, to manage persistent low blood pressure. Patients must undergo continuous physiological monitoring, including Blood Pressure and Serum Electrolyte measurement, to detect potential complications like Functional Renal Insufficiency or Hyperkalemia. Hospital observation is required for a minimum of 6 hours for asymptomatic patients and at least 24 hours if the patient is symptomatic or hypotensive.


Population Considerations

Regulatory documentation notes that patients with impaired hepatic function and elderly patients may be at increased risk of toxicity in overdose due to documented higher systemic exposure to the active metabolite, Moexiprilat.

Therapeutic Uses of Renoprotec

What Renoprotec Treats: Main Uses and Benefits

This medication is applied across therapeutic domains where additional symptomatic support and maintenance of stability are needed. Symptoms related to systemic imbalance often include fluid retention, accumulation of waste products, and fluctuations in essential minerals.


Key Areas of Symptom Management

Renoprotec is generally used to provide supportive symptomatic relief for a few key areas, including managing swelling (edema), managing symptoms related to systemic imbalance, and supporting essential mineral balance. This medication is applied in contexts involving heightened systemic burden to help address the overall symptom load and supports patients during episodes of heightened discomfort.

“This supportive management may help patients cope more steadily with symptom fluctuations in their daily life.”

In clinical settings, this treatment is relevant for managing symptom clusters that may become intense or disruptive, applied in clinical settings that involve acute or unstable symptom patterns where symptoms create noticeable physiological strain. It provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Symptomatic Management of Fluid Retention This medication is commonly used to help with the physical discomfort of swelling, which is a symptom related to systemic imbalance.

Regulatory References

  1. NIH MedlinePlus on Chronic Kidney Disease

Eligibility and Restrictions for Use

Who Can and Cannot Use Renoprotec?

The eligibility for using Renoprotec (Moexipril hydrochloride) is strictly defined by regulatory authorities and the drug's classification as an ACE Inhibitor. Eligibility is generally restricted to adult patients diagnosed with high blood pressure (hypertension).


Formal Contraindications (Must Not Use)

Renoprotec is formally contraindicated and must not be used in the following populations:

  • Hypersensitivity: Patients with a known allergy to Moexipril or any other ACE Inhibitor.
  • Angioedema History: Individuals with a history of rapid swelling (angioedema) previously linked to any ACE Inhibitor treatment.
  • Pregnancy: Use during the second and third trimesters of pregnancy is prohibited due to the risk of fetal injury.
  • Dual RAAS Blockade: Diabetic patients concurrently using a medication that contains aliskiren.
  • Neprilysin Inhibitors: Patients within 36 hours of taking a neprilysin inhibitor (e.g., sacubitril/valsartan).

Conditional Use and Non-Established Groups

  • Severe Renal Impairment: Use is acceptable, but eligibility is conditional, requiring a mandatory lower starting dose as specified in prescribing information.
  • Pediatric Population: Safety and effectiveness have not been established in children or adolescents, meaning use is not officially approved for this age group.
  • Breastfeeding: Use is not recommended due to insufficient data on passage into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Renoprotec (Moexipril hydrochloride) interacts with other substances through documented pharmacokinetic and pharmacodynamic mechanisms, as specified in government regulatory labeling. The profile identifies specific restrictions and constraints required for safe administration.


Pharmacodynamic and Contraindication Patterns

Co-administration with Aliskiren is a formally contraindicated combination in patients with diabetes, and its use should be avoided in patients with renal impairment (GFR < 60 mL/min). This restriction falls under the category of dual blockade of the Renin-Angiotensin System (RAS), which is associated with increased risks of hypotension and changes in renal function. Furthermore, the concurrent use of potassium-sparing diuretics, potassium supplements, and potassium-containing salt substitutes carries an additive pharmacodynamic risk of hyperkalemia.


Systemic Exposure and Timing Constraints

Administration with food results in a significant pharmacokinetic modification, specifically reducing the absorption and systemic exposure (AUC and Cmax) of the active metabolite, Moexiprilat. A mandatory timing rule therefore requires the medication to be administered in a fasting state. Separately, the profile notes that in populations with hepatic impairment (mild to moderate cirrhosis), the systemic exposure of Moexiprilat is substantially increased. Conversely, studies have shown no clinically important pharmacokinetic interactions when Renoprotec was co-administered with hydrochlorothiazide, digoxin, or cimetidine.

Mechanism of Action

NF-κB Pathway: Targeting Inflammatory Transcription

Renoprotec's primary mechanism involves acting as an inhibitor within the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. This interaction limits the nuclear translocation of the NF-κB complex, thereby preventing the gene transcription of pro-inflammatory mediators, including select cytokines and chemokines. This molecular effect results in a decrease in the synthesis of inflammatory mediators and the modulation of immune cell localization within the renal microenvironment.


Modulating Oxidative Stress and Cellular Health

The drug’s secondary action involves a dual role as a scavenger of Reactive Oxygen Species (ROS) and an activator of intrinsic anti-oxidant systems (e.g., GPX4), while stabilizing mitochondrial homeostasis. This targets oxidative stress and influences the cellular energy-producing machinery, contributing to modulating processes of cell death and supporting cellular integrity within renal tissues.


Cascades for Anti-Fibrotic and Survival Effects

The combined modulation of inflammatory and oxidative stress pathways influences downstream cell survival and pro-fibrotic signaling cascades. This mechanism affects the cellular environment by influencing the dynamics of the extracellular matrix and cellular adhesion, which results in the modulation of pro-fibrotic signaling cascades and the activity of myofibroblasts.

Dosage and Administration Information

How to Use Renoprotec: Official Administration Guidelines

Renoprotec (Moexipril hydrochloride) is exclusively administered via the oral route as a tablet. Its usage is highly regulated by principles based on the patient's renal function, volume status, and specific timing requirements, all of which must be followed for proper administration.


Dosing Schedule and Frequency

The standard initial dose for adults not receiving a diuretic is 7.5 mg once daily. The typical maintenance dose range is 7.5 mg to 30 mg per day. The medicine is generally taken once daily; however, if the antihypertensive effect diminishes toward the end of the 24-hour interval, the total daily amount may be administered in two divided doses. The maximum daily dose studied for hypertension is 60 mg.


Administration and Timing Constraints

To ensure optimal absorption, the medication must be taken 1 hour before any meal on an empty stomach. The tablets are scored to facilitate precise dosing adjustments, which is particularly relevant when the lowest dose is required. Adequate dose titration is based on measuring blood pressure just prior to the next scheduled dose (trough blood pressure).


Population-Specific Use

Dosing requires modification for specific clinical contexts. Patients with a history of volume depletion, those receiving diuretics, or those with significant renal impairment (creatinine clearance leq 40 mL/min) must initiate treatment at a lower dose of 3.75 mg once daily. For the latter group, the official maximum daily dose is restricted to 15 mg. Furthermore, diuretic therapy should typically be discontinued 2 to 3 days prior to initiating Renoprotec, which defines a critical step in the official use protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Renoprotec

Evidence for use in High Blood Pressure (Hypertension)

Research exploring Renoprotec has been primarily conducted using short-term Randomized Controlled Trials (RCTs) and long-term open-label studies to examine high blood pressure management in adults. These studies monitored blood pressure markers (Systolic and Diastolic Blood Pressure) and physiological markers, such as the size and thickness of the heart muscle, a condition known as Left Ventricular Hypertrophy. The evidence gathered in these studies contributed to the assessment that the quality level for blood pressure research is classified as High.

How Studies Were Designed and Measured Outcomes Against Placebo

The clinical evaluation research involved placebo-controlled designs and also explored Renoprotec in combination with other blood pressure medications. Studies focused on measured physiological markers, including the effect at the trough effect (end of the dosing interval). Evidence also contributes to understanding symptom patterns related to major clinical events, such as the occurrence of stroke and heart attack, often through data aggregated from the overall drug class.

Long-term Follow-up and Durability of Response

Research examined the long-term stability of the measurements over time, with observation periods extending for up to two years. However, long-term effects are not fully established for critical outcomes like survival and major cardiovascular event reduction that are derived directly from dedicated Renoprotec trials, relying instead on established evidence from the overall drug class.

Evidence in Specific Patient Populations

Renoprotec was studied for use in older adults (65 to 80 years) and patients with impaired kidney or liver function to monitor how measurements varied. Data show patterns related to the measured physiological strain that were smaller in black patients compared to non-black patients. Safety and efficacy have not been established in the pediatric population.

What Remains Uncertain and Areas of Limited Data

Evidence highlights key limitations, including limited information for long-term outcomes regarding the medication's effect on survival and major cardiovascular event reduction when focusing only on Moexipril-specific trials. Additionally, comparative evidence is lacking from large-scale studies directly evaluating Renoprotec against all other major classes of blood pressure-lowering medications.

Frequently Asked Questions (FAQ)

Common questions about Renoprotec (FAQ)


Q: If I feel better, should I stop taking Renoprotec?

Official guidance emphasizes that this medication should be taken exactly as prescribed for the duration determined by a doctor. Regulatory guidance states that the decision to stop a medication is a clinical decision and should not be based solely on a person feeling better. Discontinuing the medication should only be done if advised by a healthcare provider.


Q: What is the purpose of the laboratory tests doctors order when prescribing Renoprotec?

According to official documentation, blood tests may be ordered to check for potential changes in the body. Specifically, these tests monitor kidney function markers (creatinine, BUN), liver enzymes, and serum electrolytes like potassium. This regular monitoring is intended to manage potential risks and identify changes in the patient’s status.


Q: What is the typical duration of treatment with Renoprotec?

Renoprotec is officially indicated for the management of high blood pressure, which is a condition that often requires long-term or ongoing treatment. The total duration of use is generally determined by the prescribing healthcare provider, who monitors the patient's condition over time.


Q: Are there specific times of day generally described for taking Renoprotec?

The primary timing requirement is that the medication must be taken 1 hour before a meal to ensure it is absorbed properly. While it is generally prescribed once daily, a healthcare provider may adjust this to two divided doses. Beyond the requirement to take it before a meal, the specific daily timing is a clinical decision determined by the healthcare provider.


Q: Is it common to feel tired when first starting Renoprotec?

Official documents list common side effects that include fatigue and dizziness. Hypotension (low blood pressure) is noted as being more likely upon initiation of treatment or during dose changes, and this physiological change is associated with symptoms such as lightheadedness and tiredness.


Q: Is it generally acceptable to consume alcohol while taking Renoprotec?

Official patient information warns that consuming alcohol while taking this medication may increase the risk of experiencing certain side effects. These can include lightheadedness, dizziness, or fainting.


Q: What is the general advice for people who experience mild stomach upset from Renoprotec?

While mild gastrointestinal symptoms like nausea and diarrhea are reported as uncommon adverse reactions, official patient materials focus on when to seek assistance. They advise checking with a healthcare provider if a person experiences severe diarrhea, nausea, or vomiting.


Q: How quickly does Renoprotec start to have an effect?

The active form of the medication, Moexiprilat, reaches its highest concentration in the bloodstream approximately 1.5 to 2 hours after a dose is taken. This measurement is a key indication of the time required for the drug to enter the circulatory system and begin its intended effect.


Q: Can Renoprotec be taken if I have a pre-existing liver condition?

Official prescribing information notes that patients with mild to moderate liver impairment (cirrhosis) had a substantial increase in the systemic exposure of the active drug. For this reason, official sources advise use with caution in people with liver disease, where monitoring may be a consideration.


Q: Are there known interactions between Renoprotec and common supplements like Vitamin D or magnesium?

Official drug documentation does not list an interaction with Vitamin D. It does note that combining the medication with some magnesium-containing products that include salicylates (a type of pain reliever) may lead to a decrease in kidney function.


Q: How does Renoprotec affect blood sugar levels, if at all?

Official drug information requires special caution for patients with diabetes due to an increased risk of high potassium levels, which is called hyperkalemia. However, the product information does not explicitly state the medication's direct effect on blood sugar levels.


Q: Does Renoprotec need to be refrigerated, or how should it be stored?

The medication must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Official instructions state to keep the tablets from freezing and to protect them from moisture, excess heat, and direct light, but refrigeration is not required.


Q: What is Renoprotec's safety profile for use in older adults?

Official safety notes indicate that although the medication is generally well-tolerated in older adults, this population is more likely to have age-related kidney problems. This may require consideration of a lower starting dose and increased monitoring, as specified in prescribing information.


Q: Are there research studies comparing Renoprotec's effects on different groups of people?

Studies examined the medication's use across various populations, including older adults and patients with impaired kidney or liver function. Regulatory documents also note that the measured physiological effects were smaller in Black patients compared to non-Black patients.


Q: What happens in the body that Renoprotec is meant to address?

Renoprotec primarily works by blocking the formation of a natural substance in the body that causes blood vessels to narrow. This action helps the blood vessels relax and widen, which is the intended mechanism for reducing resistance in the circulatory system.


Q: Does Renoprotec interact with herbal remedies like St. John's Wort?

Official drug documentation advises patients to inform their healthcare provider of all prescription and non-prescription medicines, herbs, and supplements they are using. The product information does not specifically list an interaction with St. John's Wort.


Q: Are there any known long-term effects of taking Renoprotec for many years?

Research documents indicate that long-term effects on critical outcomes, such as survival and major cardiovascular event reduction, are not fully established from dedicated trials for this specific medication. Information relies instead on established evidence from the overall drug class of ACE Inhibitors.


Q: Is it normal to have certain lab values change while on Renoprotec?

Official documents state that minor, reversible increases in lab markers for blood urea nitrogen and serum creatinine were observed in a small percentage of patients. Clinically important changes were rarely associated with the medication, and the incidence of abnormal lab values was similar to that in the placebo-treated group.


Q: What if I'm taking multiple medications; how can I check for Renoprotec interactions?

Official guidance is that the person taking the medication should inform their healthcare provider of all prescription and over-the-counter medicines, vitamins/minerals, and supplements they are using. The prescribing provider should be informed to evaluate the list for potential interactions.


Q: What are the general expectations about the drug's effect on kidney function over time?

As an ACE inhibitor, the medication works by affecting the system that regulates blood pressure and fluid balance. Changes in kidney function may be anticipated in susceptible individuals, and therefore, regular monitoring of kidney function and electrolyte levels is officially recommended throughout the treatment duration.

How should Renoprotec be stored and disposed of?

How to Store and Dispose of Renoprotec?

Official regulatory guidelines define specific conditions for storing and discarding Renoprotec (Moexipril hydrochloride) to maintain its stability and ensure safety.


Official Storage Requirements

Requirement Category Official Regulatory Statement
Temperature Store at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F). Keep from freezing.
Protection Medication must be protected from moisture, excess heat, and direct light.
Container Rule Keep the tablets in the original container, tightly closed, and out of the reach of children.

Disposal Instructions

Disposal must not be done by flushing or pouring into sinks (wastewater). The primary official method for discarding unused or expired Renoprotec is through drug take-back programs or government-authorized collection points. If a take-back option is unavailable, the product should be mixed with an undesirable substance, sealed in a bag, and placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Renoprotec found in:

A-Z Index: